Managing bevacizumab-related toxicities in patients with colorectal cancer.
Saif
M Wasif
MW
Division of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA. wasif.saif@yale.edu
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D013923:Thromboembolism / Q000139:chemically induced / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D066246:ErbB Receptors